Chemotherapy of Prostate Cancer: Present and Future

Overview

Journal Curr Urol Rep

Publisher Current Science

Specialty Urology

Date 2003 May 21

PMID 12756087

Citations 5

Authors

Donald Trump

Yiu-Keung Lau

Affiliations

Soon will be listed here.

Abstract

The role of chemotherapy in prostate cancer continues to evolve. In men with symptomatic androgen-independent prostate cancer, significant reduction in pain and analgesic requirements are achievable with mitoxantrone and glucocorticoid combinations compared with glucocorticoids alone. However, survival rates are not improved. Taxane-based combinations with estramustine phosphate or other new agents show promise. Prostate-specific antigen response rates with these combinations appear to be 1.5 to 2 times more frequent than with mitoxantrone-based combinations. Randomized trials of taxane versus mitoxantrone-based therapies are underway. New agents and applications of current agents in adjuvant settings should be explored if survival in men with prostate cancer is to be improved.

Citing Articles

Inhibition of prostaglandin synthesis and actions contributes to the beneficial effects of calcitriol in prostate cancer.

Krishnan A, Srinivas S, Feldman D Dermatoendocrinol. 2010; 1(1):7-11.

PMID: 20046582 PMC: 2715203. DOI: 10.4161/derm.1.1.7106.

Cancer stem cells-clinical relevance.

Jones R J Mol Med (Berl). 2009; 87(11):1105-10.

PMID: 19816664 PMC: 3065719. DOI: 10.1007/s00109-009-0534-4.

Cancer Stem Cells: From Bench to Bedside.

Jones R, Matsui W Biol Blood Marrow Transplant. 2007; 13(Suppl 1):47-52.

PMID: 18167509 PMC: 1858645. DOI: 10.1016/j.bbmt.2006.10.010.

The anti-tumor efficacy of a GM-CSF-secreting tumor cell vaccine is not inhibited by docetaxel administration.

Prell R, Gearin L, Simmons A, VanRoey M, Jooss K Cancer Immunol Immunother. 2006; 55(10):1285-93.

PMID: 16408214 PMC: 11030054. DOI: 10.1007/s00262-005-0116-4.

The paradox of response and survival in cancer therapeutics.

Huff C, Matsui W, Smith B, Jones R Blood. 2005; 107(2):431-4.

PMID: 16150939 PMC: 1895602. DOI: 10.1182/blood-2005-06-2517.

References

Kantoff P, Halabi S, Conaway M, Picus J, Kirshner J, Hars V . Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol. 1999; 17(8):2506-13. DOI: 10.1200/JCO.1999.17.8.2506. View

Benson R . Mechanisms of action and clinical uses of estramustine. Cancer Invest. 1990; 8(3-4):375-80. DOI: 10.3109/07357909009012056. View

Mangelsdorf D, Koeffler H, Donaldson C, Pike J, Haussler M . 1,25-Dihydroxyvitamin D3-induced differentiation in a human promyelocytic leukemia cell line (HL-60): receptor-mediated maturation to macrophage-like cells. J Cell Biol. 1984; 98(2):391-8. PMC: 2113084. DOI: 10.1083/jcb.98.2.391. View

Zhou J, Norman A, Chen D, Sun G, Uskokovic M, Koeffler H . 1,25-Dihydroxy-16-ene-23-yne-vitamin D3 prolongs survival time of leukemic mice. Proc Natl Acad Sci U S A. 1990; 87(10):3929-32. PMC: 54017. DOI: 10.1073/pnas.87.10.3929. View

McElwain M, Modzelewski R, Yu W, Russell D, Johnson C . Vitamin D: an antiproliferative agent with potential for therapy of squamous cell carcinoma. Am J Otolaryngol. 1997; 18(5):293-8. DOI: 10.1016/s0196-0709(97)90022-3. View

Yu W, McElwain M, Modzelewski R, Russell D, Smith D, Trump D . Enhancement of 1,25-dihydroxyvitamin D3-mediated antitumor activity with dexamethasone. J Natl Cancer Inst. 1998; 90(2):134-41. DOI: 10.1093/jnci/90.2.134. View

Chott A, Sun Z, Morganstern D, Pan J, Li T, Susani M . Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of the type 1 insulin-like growth factor receptor. Am J Pathol. 1999; 155(4):1271-9. PMC: 1867033. DOI: 10.1016/S0002-9440(10)65229-7. View

Oh W, Kantoff P . Management of hormone refractory prostate cancer: current standards and future prospects. J Urol. 1998; 160(4):1220-9. View

Petrylak D, Macarthur R, OConnor J, SHELTON G, Judge T, Balog J . Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol. 1999; 17(3):958-67. DOI: 10.1200/JCO.1999.17.3.958. View

10.

Beer T, Eilers K, Garzotto M, Egorin M, Lowe B, Henner W . Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J Clin Oncol. 2002; 21(1):123-8. DOI: 10.1200/jco.2003.05.117. View

11.

Baselga J, Rischin D, Ranson M, Calvert H, Raymond E, Kieback D . Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol. 2002; 20(21):4292-302. DOI: 10.1200/JCO.2002.03.100. View

12.

Getzenberg R, Light B, Lapco P, Konety B, Nangia A, Acierno J . Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. Urology. 1998; 50(6):999-1006. DOI: 10.1016/S0090-4295(97)00408-1. View

13.

Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, Druker B . Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 1996; 56(1):100-4. View

14.

Reichel H, Koeffler H, Norman A . The role of the vitamin D endocrine system in health and disease. N Engl J Med. 1989; 320(15):980-91. DOI: 10.1056/NEJM198904133201506. View

15.

Light B, Yu W, McElwain M, Russell D, Trump D, Johnson C . Potentiation of cisplatin antitumor activity using a vitamin D analogue in a murine squamous cell carcinoma model system. Cancer Res. 1997; 57(17):3759-64. View

16.

Barton J, Blackledge G, Wakeling A . Growth factors and their receptors: new targets for prostate cancer therapy. Urology. 2001; 58(2 Suppl 1):114-22. DOI: 10.1016/s0090-4295(01)01253-5. View

17.

Culine S, Droz J . Chemotherapy in advanced androgen-independent prostate cancer 1990-1999: a decade of progress?. Ann Oncol. 2001; 11(12):1523-30. DOI: 10.1023/a:1008394823889. View

18.

Colston K, Chander S, MACKAY A, Coombes R . Effects of synthetic vitamin D analogues on breast cancer cell proliferation in vivo and in vitro. Biochem Pharmacol. 1992; 44(4):693-702. DOI: 10.1016/0006-2952(92)90405-8. View

19.

Eisman J, BARKLA D, Tutton P . Suppression of in vivo growth of human cancer solid tumor xenografts by 1,25-dihydroxyvitamin D3. Cancer Res. 1987; 47(1):21-5. View

20.

Ko Y, Small E, Kabbinavar F, Chachoua A, Taneja S, Reese D . A multi-institutional phase ii study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancer. Clin Cancer Res. 2001; 7(4):800-5. View